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1. Introduction 
Neurocysticercosis (NCC), the most common parasitic brain disease worldwide, is endemic 
in countries with poor sanitation, and is increasingly being reported in developed countries 
due to globalization and immigration. As of many decades ago innumerable papers have 
been published regarding the clinical diagnosis of NC. It has been typical to affirm that 
clinical manifestations are extremely heterogeneous because they depend on the number, 
location, size, viability, or evolutionary phase of the parasite, as well as on the 
immunological response of the patient [1,2]. One of the most intriguing aspects of NCC is 
that presumably a high percentage of the individuals harboring NCC remain asymptomatic 
[3]; however, among the symptomatic group, the only clinical manifestation in most 
patients with parenchymal NCC is seizures, and their neurological status is usually 
normal [2].  In some patients NCC develops clinical manifestations many years after the 
parasite lodges in the central nervous system [4], as either brain inflammation around the 
parasite or mass effect. It has also been stated that almost any neurological 
symptomatology may be found, ranging from mild headache or treatable acute seizures to 
very severe neurological manifestations, such as intracranial hypertension (ICH), 
dementia, or even death [5-8]. These assumptions are probably true, since empirical 
observation has shown that many of these factors are related to a specific clinical 
manifestation; however, to date there is no definitive study, using appropriate 
methodology, designed to address the precise role of each of these factors, or the 
interaction among them, on the development of symptoms or signs due to NC. This is 
why the clinical spectrum of symptomatic NCC is currently poorly understood [9].  
2. Clinical manifestations of neurocysticercosis 
A myriad of papers have reported a wide range of diverse symptoms and signs related to 
NC, such as manifestations of brainstem dysfunction, cerebellar ataxia, sensory deficits, 
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involuntary movements, stroke-like symptoms, extrapyramidal signs,  dementia, Bruns 
syndrome, Kluver-Bucy syndrome, cortical blindness, etc [2,10]; however, in some cases it is 
not possible to establish a clear cause-effect relationship between these pathologies and NC, 
and a fortuitous relationship among them may occur.  Most of this information comes from 
retrospective data based on uncontrolled studies, historical case series, and anecdotal 
reports collected mainly from hospital neurological settings.  A systematic review was 
conducted to estimate the clinical manifestation frequencies of symptomatic NCC [9]. The 
authors reviewed 1569 papers and only 21, based on minimal quality standards, were 
included in the final analysis. Most of the studies report clinical manifestations of NCC 
based on hospital medical charts, which don’t present reliable information; the majority of 
them do not provided definitions of manifestations and, if they do, they vary from study to 
study. Among NCC patients seen in neurology clinics, about 79% had seizures/epilepsy, 
38% severe headaches, 16% focal deficits, and 12% signs of increased intracranial pressure. 
Several other symptoms were also reported in less than 10% of the patients. The authors 
concluded that these estimates are only applicable to patients who are assisted in neurology 
clinics and likely over estimate the frequency of manifestations among all NCC cases [9]. 
Table 1 shows some representative studies which confirm the above mentioned clinical 
manifestations. 
Clinical manifestations of NCC are determined mainly by the location of the parasite within 
the CNS, the evolutive phase of the parasite, and the immunological response of the patient, 
expressed as severity of disease activity.  The clinical manifestations of parenchymal NCC 
are quite different from those of extraparenchymal NCC [11,12]. When the parasites are 
localized in the parenchyma, the main clinical manifestations are epileptic seizures or focal 
neurological deficits; if the parasites are localized inside the ventricles or the subarachnoid 
location there are signs and symptoms of cranial hypertension syndrome, cranial nerves 
abnormalities and hydrocephalus [12]. Regarding the parasite evolutive phase, the 
transitional or degenerative phase develops clinical manifestations due to the inflammatory 
reaction of the brain [13].  NCC predominantly affects adults in their third and fourth 
decade of life, and is relatively uncommon in children and the elderly [1,2]  Reports of NCC 
are very rarely in children younger than 2 years of age because of the prolonged incubation 
period of T solium. Most often, the disease is recognized in children older than 7, due to this 
incubation period. 
There is also clinical heterogeneity across geographical areas; most cases from the Indian 
subcontinent present single degenerative lesions, whereas those from Latin America present 
few viable cysts [14]. These differences are probably due to complex interactions between 
the host, parasite, and environmental factors [3]. Genetic differences in T. solium cysticerci 
have been reported from different countries [15,16] and may contribute towards the clinical 
variations among countries.  A genetic susceptibility to NCC has been suggested by a 
reported positive association of HLA-DRBII 13 with single, contrast enhancing CT lesions 
[17]. However, familial aggregation of seizures in first degree relatives of NCC patients with 
seizures was not found [18]. 
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Country 
(reference) 
Clinical 
manifestations 
No. 
Pts. 
Age NCC diagnostic criteria design 
Brazil, 
(Forlenza 
OV, 1997) 
Seizures 60 5%. 
depression 52% 
intracranial 
hypertension 
15% 
 
 
38 
18 to 59 
years 
old 
 
CT scans: small, 
multiple, calcifications 
or cystic, contrast 
enhanced or not, 
lesions within the 
parenchyma 
historical cases 
from hospital 
records 
Brazil 
(Loureiro  
MG et al, 
1997) 
Seizures 91%, 
headaches 23%, 
motor deficit 7%
 
44 
All ages Del Brutto et al 
diagnostic criteria * 
historical cases 
from hospital 
records 
Mexico 
(Ruiz M et 
al, 1997) 
seizures, 
intracranial 
hypertension and 
learning 
disabilities 
 
 
122 
< 17 
years 
old 
CT scan (details not 
provided) 
historical cases 
from hospital 
records 
Mexico 
(Saenz B, et 
al,  2006) 
Seizures 80% 
adults, 56% 
children 
headache 35% 
adults, 21%, 
children 
 
 
206 
All ages CT scan or MRI (details 
not provided) 
direct 
questionnaire or 
hospital records 
 
USA 
(Rosenfeld 
EA et al, 
1996) 
Seizures 87%, 
headaches 32%, 
altered mental 
status 13% 
 
 
47 
1 to 15 
years 
old 
 
CT scan or MRI  single 
or multiple 
parenchymal, 
intraventricular, spinal, 
or subarachnoid 
lesions that were 
contrast-enhancing, 
cystic, or calcified 
historical cases 
from hospital 
records 
Ecuador 
(Carpio A, 
et al. 2008) 
Seizures 62%, 
headaches 70%, 
depression 17% 
 
 
178 
All ages CT scan or MRI: One or 
more active or 
degenerative 
parenchymal cysts 
associated or not with 
an extraparenchymal 
location 
prospective cohort 
study, definitions 
of clinical 
manifestations 
 
* Reference 31 
Table 1. Clinical manifestations of neurocysticercosis 
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3. Parenchymal neurocysticercosis 
As previously stated, the most common clinical manifestation of parenchymal NCC is 
epileptic seizure, which occurs in 60-90% of cases. A clinical study including 336 patients 
[12], reported that seizures were the most common manifestation in the parenchymal 
location [88%), in comparison with the extraparenchymal location [20%); similarly, focal 
deficits or motor abnormalities were commonest in the parenchymal location [24% vs. 14%). 
Focal neurological deficits, when present, are usually transient, over a period of a few days, 
weeks, or months, with periods of remission and relapse, most likely due to different 
evolutionary stages of the parasite.  
Clinical manifestations are clearly different when comparing by age [19]. Most cases of 
childhood NCC present mild to moderate symptomatology and single lesions [20-22]. A 
study [23] specifically carried out to compare the clinical manifestations between pediatric 
and adult NCC patients reported that seizures were more frequent in children [80.4% versus 
56.1%), intracranial hypertension and headaches were more frequent in adults [27.2% versus 
15.2% and 35.1% versus 21.7%, respectively), and focal deficits were 17% in adults and 12% 
in children. Although these age-related differences seem clear, a single effect of age is 
difficult to demonstrate, since various confounding factors are probably involved [19]. 
Most paediatric cases show a single transitional cyst, also named solitary cysticercus 
granuloma [2,24].  The single transitional cyst or single enhancing lesion on CT (SECTL) or 
hyperintense lesion on magnetic resonance imaging (MRI), is a common finding in patients 
with newly identified seizures in developing countries. These patients, mainly children and 
young adults, have some benign and transitory clinical manifestations, predominantly 
partial or partial secondary generalized seizures, and occasionally Todd’s paresis or focal 
neurological deficits. SECTL tend to resolve spontaneously, without anticysticercal drugs or 
surgery, since the parasite is already in the degenerative phase and will eventually 
disappear or become calcified. 
Symptomatology of altered mental state and psychiatric manifestations remains poorly 
described in the literature [9]. In two studies [25,26] which provided definitions of clinical 
manifestations, depression was reported about 53% and 15%, respectively. Differences on 
gender have also been identified. Inflammation surrounding parenchymal cysticerci is more 
intense in women [19]; and multiple degenerating parasites localized in the parenchyma are 
more frequently reported in young women.  Regardless of the localization of the parasite, 
the inflammatory response, as expressed by cerebrospinal fluid (CSF) cellularity is also more 
intense in women [3].  A recent prospective study [19] confirms that there are significant 
gender and age differences in the local immune response, even after adjusting for 
differences in healthcare access. 
4. Extraparenchymal neurocysticercosis 
The extraparenchymal location (around 15–30% of cases) develops different clinical 
manifestations. Headache and signs of intracranial pressure are more frequent in the 
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extraparenchymal location [88%), in comparison with the parenchymal location (10%). [12] 
When cysticerci are located inside the ventricular system, life-threatening acute intracranial 
hypertension as a result of hydrocephalus may occur; as a consequence, severe headache, 
dizziness and consciousness alteration are the predominant clinical manifestations [5,27].  
Cysts in the subarachnoid space may lodge in the Sylvian fissure or basal cisterns and grow 
to a big size (racemose form), causing intracranial hypertension. This is associated with an 
intense inflammatory reaction, and fibrosis and progressive thickening of the leptomeninges 
at the base of the brain [13]. There is an obstruction of the CSF circulation, resulting in 
hydrocephalus and progressive intracranial hypertension. Inflammation of meninges, 
cranial nerve involvement, chiasmatic syndrome, and cerebral infarcts secondary to 
vasculitis may develop [5,6]. When hydrocephalus due to cysticercotic meningitis is present, 
the mortality rate is high (50%), and most patients die within 2 years after CSF shunting 
[6,8]. This is why ventricular and basal cisternal locations are considered to be malignant 
forms of NCC [28]. In cases with NCC meningitis, cerebrospinal fluid (CSF) may show mild 
elevation of protein, hypoglycorrhachia and lymphocytic pleocytosis, which is similar to 
other chronic basal meningitis, such as tuberculosis and mycosis.[2] 
Spinal cord cysticercosis is rare. Patients experience nonspecific clinical manifestations, such 
us nerve root pain or spinal cord compression syndromes, according to the level of the 
lesion [29]. Severe forms of NCC may exceptionally occur, including cysticercotic 
encephalitis, which result in permanent neurologic sequel, such as amaurosis. 
Hydrocephalus and intraventricular NCC is extremely rare in children [23,30] 
5. Immunological and imaging diagnosis 
Two main techniques, the Enzyme-linked Immunosorbent Assay (Ab-ELISA) and Enzyme-
Linked Immunoelectrotransfer Blot (EITB) Assay, are used for immunological diagnosis of 
NCC. ELISA test for antibodies or antigen detection have showed higher sensitivities and 
specificities in CSF than in sera [31]. EITB sensibility seems to be not significantly different 
in sera and CSF while specificity is higher in CSF [32]. Sensibility of either tests falls in cases 
of single cysts in parenchyma or when they are calcified [33]. In patients with reliable 
diagnosis of NCC by imaging studies, immunological test is not required, since a negative 
test will not discard a NCC. When imaging of extraparnechymal cysts is doubtful, 
determination of antigens by ELISA in CSF may be helpful [31].  
Computed tomography and magnetic resonance imaging have been useful in the study of 
the parasite evolution within the brain parenchyma [2]. Once the oncosphere has passed 
into the parenchyma, it grows and evolves through vesicular, colloidal, granular-nodular, 
and calcified phases [13]. In the vesicular phase the larva lives inside a translucent liquid-
filled cystic structure surrounded by a thin membrane. The CT scan depicts circumscribed, 
rounded, hypodense areas, varying in size and number, without enhancement by contrast 
media [34]. With the MRI, the vesicular larva appears with a CSF-like intensity signal on all 
sequences.  Both MRI and CT may show a high intensity, 2-3 mm. mural nodule, depicting 
the scolex, in the interior of some vesicular cysts (Figure 1). It is better seen on fluid 
attenuated inversion recovery (FLAIR) sequence [35]. 
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A: vesicular cysts B: colloidal cysts C: nodular cysts D: calcified cysts  
Figure 1. Imaging of parenchymal neurocysticercosis 
As the cyst degenerates, the CT scan shows an annular or nodular enhancement surrounded 
by perilesional edema. In this stage, the fluid content gives slightly higher signal than CSF 
and is sometimes isodense with the parenchyma on MRI-T1 and/or proton density-
weighted, and high signal on T2 images. The capsule shows higher signal than the adjacent 
brain with thick ring enhancement on T1 images, while on T2 images there is a low ring 
signal surrounded by high signal lesion, due mostly to edema. Finally, when the cyst dies it 
may disappear or become an inactive calcified nodule of homogenous high density on CT, 
or low intensity on proton-weighted MRI [2] (Figure 1). 
A 
D C 
B 
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A: Cyst in the fourth ventricle B: Racemose cysts in the basal subarachanoid space C: cysts in the prepontine cisternal 
space (MRI FIESTA sequence)  D: Racemose cysts in the degenerative stage 
Figure 2. Imaging of extraparenchymal neurocysticercosis 
Extraparenchymal NCC is more difficult to detect by imaging because the attenuation and 
signal intensity of the cyst’s content is similar to that of CSF, the cystic wall is usually very 
thin and the cysts lack frequently of a scolex and generally not enhanced after contrast 
administration. In these cases, new MRI techniques such as fluid attenuated inversion 
recovery (FLAIR) and fast imaging employing steady-state acquisition (FIESTA) sequences, 
that seems to permit a better diagnosis (34-36) (Figure 2) . A common neuroimaging finding 
is hydrocephalus related to inflammatory occlusion of Luschka and Magendie foramina and 
C 
A B
D
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basal fibrous arachnoiditis [36]. Cysts located within CSF cisterns usually have a 
multilobulated appearance (racemose form), displacing neighboring structures as a mass 
occupying lesion  (Figure 2).  
6. Difficulties with clinical diagnosis of neurocysticercosis 
Del Brutto et al. proposed a diagnostic criterion for NCC in 2001 [37]. In spite of the fact that 
this proposal has not been validated so far, it has been an important contribution to current 
NCC knowledge. This proposal includes four categories of criteria—absolute, major, minor, 
and epidemiologic. A combination of these criteria results in degrees of diagnostic certainty: 
definitive and probable. Diagnosis of definitive NCC is made by the presence of one 
absolute criterion or of two major plus one minor or one epidemiologic criterion [37].  
These diagnostic criteria may be useful to identify patients with mainly parenchymal forms 
of NC, but it is not for patients with extraparenchymal forms of NCC [31]. Among minor 
criteria are considered “manifestations suggestive of neurocysticercosis” which include  
seizures, focal neurologic deficits, increased intracranial pressure, and intellectual 
deterioration, which are predominantly  related to parenchymal location of lesions, but not 
necessarily to extraparenchymal clinical manifestations such us those  associated with 
intraventricular cysts or NCC meningeal inflammation.  Among absolute criteria are 
considered “Cystic lesions showing the scolex on CT or MRI” or “spontaneous resolution of 
small single enhancing lesions” It is extremely rare to see scolex on CT or MRI inside the 
ventricles or the subarachnoid location, and it is also very difficult  to demonstrate  
spontaneous resolution of small single enhancing lesions in the extraparenchymal location.  
This diagnostic criteria proposal may be a source of bias even in the event of diagnosing 
parenchymal NC. For example, a patient who lives in any country where cysticercosis is 
endemic (epidemiologic criterion), with seizure or headache (1 minor criterion), a CT 
showing a calcification (one major criterion), and a positive serum enzyme-linked 
immunoelectrotransfer blot assay –EITB- (one major criterion), according to this proposal, 
should be categorized as “definitive NC”. However, it could be erroneous to diagnose this 
patient as having NC, since headache is extremely unspecific, a positive EITB means just 
exposure to the parasite, and a calcification could correspond to many other pathologies, but 
not necessarily NC.  The selection of these patients in some reports, especially those 
community-based, is probably over-diagnosing NC.  
There are additional problems related to this proposal that could lead to a misleading 
diagnosis. According to these diagnosis criteria, two major criteria fulfill a definite NCC 
diagnosis criterion. In this context, a patient with a positive immunologic test for the 
detection of anticysticercal antibodies (major criterion)  plus a plain X-ray films showing 
“cigarshaped” calcifications in thigh and calf muscles (major criterion) could be diagnosed 
as NC. It is very hard to accept that such a patient may unquestionably have cysticerci in the 
brain.  Some authors have claimed that the generalized use of Del Brutto et al [38 ] criteria 
have created some distortion in the present perception of NCC [31] A broad consensus now 
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exists that these criteria should be revised to incorporate current scientific knowledge, in 
order to achieve a new consensus on the diagnosis of NCC. 
7. Conclusion 
So far, diagnosis of NCC is mainly done by neuroimaging. New imaging techniques have 
improved detection of the scolex inside the cysts, which can be considered pathognomonic 
of neurocysticercosis There is no a typical clinical manifestation of NCC. Prospective cohort 
studies addressed to analyzing NCC clinical manifestations, including definitions and 
appropriate methodology, which make them comparable, are extremely scarce in the 
medical literature. Location of the parasite in the CNS, age, sex, and immunological 
response of the patient, all seem to play an important role in occurrence of symptoms and 
signs; however, the relative contribution of these factors, alone or in combination, is still 
unknown.  
In the parenchymal location, seizures are the most frequent clinical manifestation, followed 
by headache, motor focal deficits, and psychiatric and cognitive symptomatology.  These 
clinical manifestations may have periods of remission and exacerbation, according to the 
evolutionary phase of the parasite inside the parenchyma. Diagnosis of extraparenchymal 
NCC is even more difficult, considering that unspecific symptoms and signs of intracranial 
hypertension and meningitis may occur, with or without signs of CSF inflammation.  The 
clinical manifestations due to parenchymal location are usually benign and are sometimes 
transitory in time; on the contrary, clinical presentation of the extraparenchymal location is 
life-threatening and may develop permanent sequels. 
Properly-designed studies with similar methodology are needed to learn more about the 
natural history of the disease and the true distribution of clinical manifestations. There is 
also an urgent need to develop new consensus diagnosis criteria for NC. 
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